title: Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine.
abstract: Thalassemia major is an inherited form of chronic hemolytic anemia that results in iron overload due to regular blood transfusions. Deferoxamine is used as chelating agentfor treatment ofpatients with chronic iron overload worldwide. Anaphylactic reaction to deferoxamine is rare, and the mechanism ofdeferoxamine-induced anaphylaxis is not well understood. Only afewpediatric cases ofsuccessful desensitization for deferoxamine hypersensitivity have been described, and a different protocol has been used in each report. We report a case ofanaphylaxis to deferoxamine in a thirteen-years-old Thai boy with Hemoglobin E/β-thalassemia disease who underwent successful desensitization. He had been receiving blood transfusions since the age often months. At age eleven, the patient began treatment with deferoxamine. Treatment was interrupted after the occurrence ofanaphylaxis, with urticaria, wheezing and gastrointestinal symptoms. A skin prick test was positive, indicating a type 1 hypersensitivity reaction. Deferoxamine desensitization was attempted with various differentprotocols. Finally, the patient could tolerate deferoxamine therapy at the dose previously administered. We proposed this modified subcutaneous desensitization protocolforpediatric cases that develop allergic reactions to deferoxamine.
authors.forename: Pacharapan
authors.initials: P
authors.lastname: Surapolchai
authors.forename: Orapan
authors.initials: O
authors.lastname: Poachanukoon
authors.forename: Wallee
authors.initials: W
authors.lastname: Satayasai
authors.forename: Pakatip
authors.initials: P
authors.lastname: Silapamongkonkul
mesh_terms: D000293:Adolescent; D000707:Anaphylaxis / Q000139:chemically induced / Q000517:prevention & control*; D001803:Blood Transfusion; D003676:Deferoxamine / Q000008:administration & dosage* / Q000009:adverse effects; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced / Q000517:prevention & control; D007279:Injections, Subcutaneous; D019190:Iron Overload / Q000188:drug therapy*; D008297:Male; D017262:Siderophores / Q000008:administration & dosage* / Q000009:adverse effects; D012882:Skin Tests; D017086:beta-Thalassemia / Q000628:therapy*
chemical_list: D017262:Siderophores; D003676:Deferoxamine